HANSOH PHARMA - VOLUNTARY ANNOUNCEMENT -

THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR FOURTH-GENERATION EGFR-TKI HS-10504 TABLETS FOR NSCLC

Hansoh Pharmaceutical Group Company Limited 翰 森 製 藥 集 團 有 限 公 司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED

DRUG FOR FOURTH-GENERATION EGFR-TKI HS-10504 TABLETS FOR NSCLC

The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited (the "Company" and together with its subsidiaries, the "Group") is pleased to announce that, on May 21, 2026, the Group's self-developed fourth-generation Epidermal Growth Factor Receptor ("EGFR") Tyrosine Kinase Inhibitor ("TKI") HS-10504 tablets has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (NMPA) of China, with the proposed indication for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the EGFR C797S mutation after prior EGFR-TKI

therapy failure.

By Order of the Board Hansoh Pharmaceutical Group Company Limited Zhong Huijuan Chairlady

Hong Kong, May 21, 2026